Cynata Therapeutics Limited

ASX:CYP Stok Raporu

Piyasa değeri: AU$42.5m

Cynata Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Cynata Therapeutics's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been declining at an average rate of 7.6% per year.

Anahtar bilgiler

-16.2%

Kazanç büyüme oranı

-3.5%

EPS büyüme oranı

Biotechs Sektör Büyümesi9.6%
Gelir büyüme oranı-7.6%
Özkaynak getirisi-135.0%
Net Marj-420.8%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Sep 21
Here's Why We're Watching Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

May 29
Will Cynata Therapeutics (ASX:CYP) Spend Its Cash Wisely?

We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

Feb 09
We're A Little Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Rate

We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How Cynata Therapeutics (ASX:CYP) Uses Its Cash Hoard To Grow

We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Sep 09
We Think Cynata Therapeutics (ASX:CYP) Can Easily Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

May 26
Here's Why We're Not At All Concerned With Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

Dec 31
Here's Why We're Not Too Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn Situation

We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Aug 11
We're Not Worried About Cynata Therapeutics' (ASX:CYP) Cash Burn

Gelir ve Gider Dağılımı

Cynata Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

ASX:CYP Gelir, gider ve kazançlar (AUD Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 242-1029
31 Mar 242-12211
31 Dec 232-14212
30 Sep 232-14212
30 Jun 232-14212
31 Mar 232-12211
31 Dec 223-929
30 Sep 225-729
30 Jun 228-539
31 Mar 228-556
31 Dec 218-474
30 Sep 215-654
30 Jun 212-834
31 Mar 212-725
31 Dec 203-606
30 Sep 205-516
30 Jun 207-426
31 Mar 206-636
31 Dec 194-846
30 Sep 193-836
30 Jun 191-826
31 Mar 191-724
31 Dec 181-623
30 Sep 181-523
30 Jun 181-513
31 Mar 181-513
31 Dec 171-513
30 Sep 172-513
30 Jun 172-513
31 Mar 172-414
31 Dec 162-304
30 Sep 161-414
30 Jun 161-514
31 Mar 161-523
31 Dec 151-532
30 Sep 151-422
30 Jun 150-412
31 Mar 150-321
31 Dec 140-321
30 Sep 140-321
30 Jun 140-321
31 Mar 140-320
31 Dec 130-210

Kaliteli Kazançlar: CYP is currently unprofitable.

Büyüyen Kar Marjı: CYP is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.

Büyüme Hızlandırma: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.5%).


Özkaynak Getirisi

Yüksek ROE: CYP has a negative Return on Equity (-135.02%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin